Jennifer Chapman Fredricks

Jennifer Chapman Fredricks

Auto-generated profile, based on publicly available information

Jennifer Chapman Fredricks

University of Miami 11 Department of Pathology Miami, Florida

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JCJennifer R. Chapman
Jennifer R. Chapman
ABAlyssa C. Bouska
Alyssa C. Bouska
WZWeiwei Zhang
Weiwei Zhang
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
ILIzidore S. Lossos
Izidore S. Lossos
JSJoo Y. Song
Joo Y. Song

1 July 2018 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
MKMahsa Khanlari
Mahsa Khanlari
JRJuan Carlos Ramos
Juan Carlos Ramos
SSSandra Patricia Sanchez
Sandra Patricia Sanchez
JCJeong Hee Cho-Vega
Jeong Hee Cho-Vega
AAAlexandra Amador
Alexandra Amador
JCJennifer R. Chapman
Jennifer R. Chapman
Adult T-cell leukemia/lymphoma, an aggressive T-cell neoplasm, is causally linked to human T-cell lymphotropic virus type 1 and based on this association has a distinct geographic distribution. In our United States-based practice, whose population is enriched for immigrants from human T-cell lymphotropic virus type 1 endemic areas, we have identified that a subset of adult T-cell leukemia/lymphoma, in the absence of human T-cell lymphotropic virus type 1 identification, are indistinguishable from other more common T-cell neoplasms. We retrospectively gathered serology results for anti-human T-cell lymphotropic virus type 1/2 antibody in patients diagnosed with T-cell neoplasms at our institution. A total of 220 human T-cell lymphotropic virus type 1/2 positive patients with T-cell neoplasms were identified; 199 (91%) were correctly classified as adult T-cell leukemia/lymphoma or provisionally as peripheral T-cell lymphoma (serology testing pending). Twenty-one cases (9%) were initially misclassified, including the following: 13 presenting with skin +/− peripheral blood involvement and misclassified as mycosis fungoides/Sezary syndrome; 7 with lymphomatous disease, absence of leukemic involvement, and diffuse CD30 expression, misclassified as ALK- negative anaplastic large-cell lymphoma; 1 thought to represent T-prolymphocytic leukemia with TCL-1 gene rearrangement and diffuse marrow involvement. We also present an example of adult T-cell leukemia/lymphoma, which mimicked lymphoepithelioid variant of peripheral T-cell lymphoma also with diffuse marrow involvement. A subset of adult T-cell leukemia/lymphoma can closely mimic a variety of other more common T-cell neoplasms. Due to its extreme clinicopathologic heterogeneity, identification of adult T-cell leukemia/lymphoma requires a high level of suspicion based on patient demographic alone, which should prompt anti-human T-cell lymphotropic virus type 1/2 serology testing in all T-cell neoplasms developing in patients of appropriate demographic. Absence of high level of suspicion, adult T-cell leukemia/lymphoma is easily misclassified.

15 January 2022 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
MKMahsa Khanlari
Mahsa Khanlari
JCJennifer R. Chapman
Jennifer R. Chapman
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma and originates from germinal center B-cells (centrocytes and centroblasts) of the lymphoid follicle. Tumorigenesis is believed to initiate early in precursor B-cells in the bone marrow (BM) that acquire the t(14;18)(q32;q21). These cells later migrate to lymph nodes to continue their maturation through the germinal center reaction, at which time they acquire additional genetic and epigeneticabnormalities that promote lymphomagenesis. FLs are heterogeneous in terms of their clinicopathologic features. Most FLs are indolent and clinically characterized by peripheral lymphadenopathy with involvement of the spleen, BM, and peripheral blood in a substantial subset of patients, sometimes accompanied by constitutional symptoms and laboratory abnormalities. Diagnosis is established by the histopathologic identification of a B-cell proliferation usually distributed in an at least partially follicular pattern, typically, but not always, in a lymph node biopsy. The B-cell proliferation is biologically of germinal center cell origin, thus shows an expression of germinal center-associated antigens as detected by immunophenotyping. Although many cases of FLs are typical and histopathologic features are straightforward, the biologic and histopathologic variability of FL is wide, and an accurate diagnosis of FL over this disease spectrum requires knowledge of morphologic variants that can mimic other lymphomas, and rarely non-hematologic malignancies, clinically unique variants, and pitfalls in the interpretation of ancillary studies. The overall survival for most patients is prolonged, but relapses are frequent. The treatment landscape in FL now includes the application of immunotherapy and targeted therapy in addition to chemotherapy.

13 January 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
JCJames Cerhan
James Cerhan
MMMathew S. Maurer
Mathew S. Maurer
BLBrian K. Link
Brian K. Link
AFAndrew L. Feldman
Andrew L. Feldman
THThomas M. Habermann
Thomas M. Habermann
CFChristopher R. Flowers
Christopher R. Flowers

1 March 2018 in Laboratory Investigation
Verified
Journal Article
Closed access
JCJennifer Chapman
Jennifer Chapman
JGJulia T Geyer
Julia T Geyer
MKMahsa Khanlari
Mahsa Khanlari
AMAdrienne Moul
Adrienne Moul
CCCarmen Casas
Carmen Casas
AOAttilio Orazi
Attilio Orazi

19 October 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
NNNina Nguyen
Nina Nguyen
SCSana Chaudhry
Sana Chaudhry
TTTULASIGERI M TOTIGER
TULASIGERI M TOTIGER
RDRobert Diaz
Robert Diaz
EREvan Roberts
Evan Roberts
JTJustin Taylor
Justin Taylor
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the overall patient population. Selinexor is an inhibitor of nuclear export that is FDA-approved for patients with multiple myeloma refractory to multiple lines of therapy. Here, we report that in four patients with multiple myeloma with t(11;14), the concomitant administration of venetoclax and selinexor was safe and associated with disease response. Moreover, the combination was synergistic in t(11;14) multiple myeloma cell lines and caused decreased levels of Cyclin D1 (which is overexpressed due to the CCND1-IGH fusion) when given in combination as compared to single agents. These data suggest that the combination of venetoclax and selinexor is effective and t(11;14) may serve as a therapeutic marker for response and target for future clinical trials.